DGAT. 1. Viking shall pay Metabasis the following one-time, non-refundable milestone payments with respect to Licensed Products containing a DGAT-1 Compound as follows: The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a DGAT-1 Compound reach or surpass […***…] […***…] The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a DGAT-1 Compound reach or surpass […***…] […***…] The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a DGAT-1 Compound reach or surpass […***…] […***…]
Appears in 3 contracts
Samples: Master License Agreement (Viking Therapeutics, Inc.), Master License Agreement (Viking Therapeutics, Inc.), Master License Agreement (Viking Therapeutics, Inc.)
DGAT. 1. Viking shall pay Metabasis the following one-time, non-refundable milestone payments with respect to Licensed Products containing a DGAT-1 Compound as follows: The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a DGAT-1 Compound reach or surpass […***…] […***…] The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a DGAT-1 Compound reach or surpass […***…] […***…] The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a DGAT-1 Compound reach or surpass […***…] […***…]
Appears in 1 contract
Samples: Master License Agreement (Ligand Pharmaceuticals Inc)
